Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients

• Coherus BioSciences Inc (NASDAQ: CHRS) announced the final overall survival (OS) results of the JUPITER-02 Phase 3 study of toripalimab in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

• The data were presented at the American Society for Clinical Oncology Annual Meeting.

• The final analysis demonstrated a statistically significant and clinically meaningful improvement in OS for NPC patients treated with toripalimab combined with gemcitabine and cisplatin chemotherapy versus chemotherapy treatment alone.

• Also Read: Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'

• Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients.

• Median OS was not reached in the toripalimab arm versus 33.7 months for chemotherapy alone.

• The FDA is currently reviewing the Biologics License Application (BLA) for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma.

• In May 2023, FDA completed the required pre-licensing inspection of partner Shanghai Junshi Biosciences Ltd's toripalimab manufacturing site in China.

• Coherus projects potential approval in Q3 2023 and plans to launch toripalimab in the U.S. directly if approved.

• No new safety signals were identified in the toripalimab arm.

• Price Action: CHRS shares are up 6.02% at $5.28 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.